Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies utilizing its proprietary lipid nanocrystal delivery technology. The platform encapsulates small molecules and oligonucleotides to facilitate targeted, extrahepatic cellular delivery without toxicity, targeting applications in oncology and inflammation. The company's lead product candidate is MAT2203, an oral formulation of the potent antifungal agent amphotericin B engineered to treat life-threatening invasive fungal infections, including invasive aspergillosis, cryptococcal meningitis, and invasive candidiasis. The company develops these therapeutic candidates primarily for patients facing serious fungal infections who have limited or no alternative treatment options.

The company maintains its principal executive offices in Bedminster, New Jersey. Its clinical development activities have included approximately 65 planned clinical investigator sites across the United States. Following corporate restructuring, Matinas BioPharma actively seeks strategic partnerships to advance its late-stage clinical programs.

Summary of the business section of Matinas BioPharma's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of March 31, 2026, we had two full time employees and retained the services of two independent contractors/consultants.”